CNBC host Jim Cramer continues to pound the table on Eli Lilly’s (LLY) stock. The host of the TV show “Mad Money” continues to be a cheerleader for LLY stock, saying repeatedly that the pharmaceutical ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market potential.

Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...

Eli Lilly & Co.’s shares saw the biggest one-day drop since 2008 after CVS Health Corp. announced a plan to drop its blockbuster weight-loss drug Zepbound from its preferred list, making rival ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

* An analyst from Guggenheim persists with their Buy rating on Eli Lilly, maintaining a target price of $928. * Reflecting concerns, an analyst from HSBC lowers its rating to Reduce with a new ...

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

Indianapolis-based Eli Lilly and Co. on Thursday posted 45% revenue growth in the first quarter of 2025 that topped Wall Street expectations, but stock prices tumbled more than 10% by midday after ...

When Eli Lilly & Co. on Tuesday announced pricing and packaging changes for its popular weight-loss drug Zepbound, the drugmaker said it was expanding access for people living with obesity — but ...

Eli Lilly CEO Dave Ricks said the drugmaker can help "respond" to national security concerns around cheaper essential medicines as pharmaceutical-specific tariffs loom.

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (LLY 2.01%) stock cut his price target on the pharmaceutical giant.